SYDNEY & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus Inc., the global leader in genome informatics and data management, today announced that the Garvan Institute of Medical Research in Sydney, Australia has selected the DNAnexus Platform to power its new Genome.One clinical whole genome testing company.
“We are proud to be the bioinformatics platform powering one of the world’s first clinical whole genome testing services, and to help Garvan expand their business with a new clinical diagnostics company," said Richard Daly, CEO of DNAnexus. "By relying on DNAnexus’ proven technology platform to securely manage genomic data, Genome.One can focus on advancing disease diagnosis with whole genome sequencing.”
“Our vision at Garvan is to make genomic information available and beneficial to all, whether in research or clinical settings,” said Marcel Dinger, Head of the Garvan Institute’s Kinghorn Centre for Clinical Genomics. “Our centre has been using the DNAnexus Platform for its genomics-based research initiatives. A key component in our pipeline was the ability to securely manage a tremendous amount of sensitive data.”
Garvan uses DNAnexus to manage, analyze, and secure the massive quantities of genomic data generated by the center’s leading NGS technology including Illumina’s HiSeq X Ten. Garvan uses the DNAnexus Platform to support complex, multi-institution global collaborations as well as high-speed, cost-efficient analysis and delivery of sequence data across a worldwide network.
The Garvan Institute’s new company, Genome.One offers clinical whole-genome sequencing services for diagnosing rare and genetic conditions. Genome.One represents the clinical extension of the Kinghorn Centre for Clinical Genomics (KCCG), and benefits from the nearly 18-month relationship between DNAnexus and the Garvan Institute.
Rather than traditional tests that analyze a single gene or multi-gene panel, this new service has the capacity to sequence and analyze the entire genome, including all twenty thousand genes, in a single test. The new service provides a fast, accurate and comprehensive service, and is expected to increase the diagnosis rates of rare disorders from around twenty percent to forty-sixty percent.
DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomics, operating in North America, Europe, Asia-Pacific (including China), South America, and Africa. The secure, scalable, and collaborative cloud-based DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs globally. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.
About the Garvan Institute of Medical Research
The Garvan Institute of Medical Research is one of Australia's largest medical research institutions and is at the forefront of next-generation genomic sequencing in Australia. Garvan’s main research areas are: cancer, diabetes and metabolism, immunology and inflammation, osteoporosis and bone biology, and neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. In 2012, Garvan established Australia’s first purpose‐built facility for undertaking clinical-grade genome sequencing and large-scale research projects. The Kinghorn Centre for Clinical Genomics (KCCG) researchers undertake collaborative projects and genome‐based studies to improve genome interpretation, with the aim of advancing the use of genomic information in patient care.
Genome.One (www.genome.one) is a pioneering health information company providing genetic answers to life’s biggest health questions through clinical Whole Genome Sequencing. Genome.One aims to enhance the lives of patients, families and communities across the world. Genome.One is a wholly owned subsidiary of the Garvan Institute of Medical Research, Sydney, Australia.